Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Trial Profile

An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jan 2019

At a glance

  • Drugs Eribulin (Primary) ; Eribulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 10 Jan 2019 Planned number of patients changed from 73 to 103.
    • 30 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
    • 10 Oct 2018 Planned number of patients changed from 63 to 73.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top